Source: International Congress 2019 – Novel findings from asthma clinical trials
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Hardy (Wellington, New Zealand), C. Baggott (Wellington, New Zealand), J. Fingleton (Wellington, New Zealand), H. Reddel (Sydney, Australia), R. Hancox (Hamilton, New Zealand), M. Harwood (Auckland, New Zealand), A. Corin (Tauranga, New Zealand), J. Sparks (Wellington, New Zealand), D. Hall (Wellington, New Zealand), D. Sabbagh (Wellington, New Zealand), S. Mane (Wellington, New Zealand), S. Vohlidkova (Wellington, New Zealand), J. Martindale (Wellington, New Zealand), M. Williams (Wellington, New Zealand), P. Shirtcliffe (Wellington, New Zealand), M. Holliday (Wellington, New Zealand), M. Weatherall (Wellington, New Zealand), R. Beasley (Wellington, New Zealand). Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma. 5332

Member's Comments

No comment yet.

Related content which might interest you: Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma Source: Eur Respir J 2016; 47: 981-984 Year: 2016 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double-blind study Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Efficacy of budesonide/formoterol maintenance and reliever therapy in mild asthma Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma Source: ERJ Open Res, 7 (4) 00271-2021; 10.1183/23120541.00271-2021 Year: 2021 Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013